← Eichor
Study identifier: NCT05445804 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Oral Cannabidiol for Tobacco Cessation

Condition: Tobacco Use · Tobacco Smoking · Tobacco Dependence  ·  Sponsor: Johns Hopkins University

PhasePhase 1
Planned participants50
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.

This description comes directly from the study's public registry record.

Talk to the study team

Dustin C Lee, PhD  ·  410-550-4035  ·  dlee214@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns Hopkins Behavioral Pharmacology Research UnitBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05445804